Biofrontera Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative dermatological therapies, with a particular emphasis on skin cancer treatments. The company's flagship product, Ameluz, is a leading therapy for actinic keratosis, supported by a sophisticated photodynamic therapy system that significantly improves patient outcomes. With a robust pipeline aimed at expanding its product offerings and global market presence, Biofrontera is strategically positioned to capitalize on the increasing demand for effective skin cancer solutions and to forge…